ENT Medical News about oral cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Appropriate Antibiotic Use for Acute Otitis Media

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis
Carcinogenesis, 07/31/09

Chung YL et al. – Epigenetic therapy using the HDAC inhibitor as an adjuvant to radiotherapy for chemical–induced oral cancer may provide a promising strategy combining the prevention of radiation–induced oral mucositis and the inhibition of oral carcinogenesis.

<< Previous
Worsening of Nose Bleeding Heralds High Cardiac Output State in...

Next >>
Expenses Hurt Omnicell's Financials

Oral cancer and polymorphism of ethanol metabolising genes
Oral Oncology, 11/12/09 Relevance Score: 70%

Quantification of betel quid chewing and cigarette smoking in oral cancer patients
Community Dentistry and Oral Epidemiology, 11/17/09 Relevance Score: 69%

Transactivation and expression patterns of Jun and Fos/AP-1 super-family proteins in human oral cancer
International Journal of Cancer, 11/10/09 Relevance Score: 68%

Saliva as a tool for oral cancer diagnosis and prognosis
Oral Oncology, 10/21/09 Relevance Score: 68%

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
Journal of Clinical Oncology, 10/16/09 Relevance Score: 68%